Vital Molecular Differences Found in Neuroendocrine Tumor Subtypes
September 23rd 2016A genomic analysis of poorly differentiated neuroendocrine tumors from primary lung and gastrointestinal sites underscores the diversity of these tumors and the evolving need to move toward precision medicine when it comes to treating patients with these malignancies.
Molecular Imaging May Help Tailor Breast Cancer Therapies
August 13th 2015Although many drugs are under study for patients with metastatic breast cancer, there is a pressing need to establish methods of predicting response and improving drug delivery, and researchers are looking toward molecular imaging techniques to help reach those goals.
Dr. Charles Ryan on Abiraterone in mCRPC
March 9th 2015Charles J. Ryan, MD, Professor of Clinical Medicine, Urology, Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco (UCSF), discusses the effects he has seen abiraterone have in patients with metastatic castration-resistant prostate cancer (mCRPC).